Allogeneic hematopoietic cell transplantation (HCT) using reduced-intensity conditioning (RIC) has lower morbidity and mortality compared to transplantation using myeloablative conditioning (MAC). The syndrome of alveolar hemorrhage, a life-threatening pulmonary complication of HCT, has not been well described after RIC HCT. We reviewed prospectively collected data on 206 RIC and 1112 MAC HCT performed between 1995 and 2004 to study the impact of conditioning regimen on the clinical features and outcome of alveolar hemorrhage. Alveolar hemorrhage occurred in 18 RIC HCT recipients (cumulative incidence 8% (95% confidence intervals (CI), 5-11%)) and 85 MAC HCT recipients (cumulative incidence 7% (95% CI, 6-8%), P ¼ 0.56). The clinical presentation of hemorrhage in both cohorts was similar. Survival at 60 days from the onset of hemorrhage was 28% (95% CI, 7-49%) for RIC group compared to 26% (95% CI, 17-35%) after MAC HCT (P ¼ 0.56). Reducing the intensity of preparative regimen does not protect against post transplant alveolar hemorrhage. Alveolar hemorrhage occurring after RIC or MAC HCT has similar incidence, clinical presentation, and associated high mortality.
Introduction
Alveolar hemorrhage is a life-threatening pulmonary complication of allogeneic hematopoietic cell transplantation (HCT). In patients undergoing allogeneic HCT using myeloablative conditioning (MAC), the incidence of alveolar hemorrhage ranges from 5 to 8% and mortality rates of more than 70% have been reported. [1] [2] [3] [4] Allogeneic HCT using reduced-intensity conditioning (RIC) regimens is being increasingly used for the treatment of a variety of hematologic disorders and has been shown to lead to longterm engraftment, exhibit a graft-versus-malignancy effect, and result in significantly lower transplant-related morbidity and mortality. 5, 6 However, the incidence, clinical presentation, and outcome of alveolar hemorrhage following RIC allogeneic HCT is not known. We conducted an analysis in a large cohort of allogeneic HCT recipients to compare alveolar hemorrhage following transplantation using RIC or MAC regimens.
Materials and methods

Patients
Prospectively collected data from the University of Minnesota Bone Marrow Transplant Biostatistics Database was reviewed for pulmonary complications in 1318 patients who underwent allogeneic HCT (RIC ¼ 206, MAC ¼ 1112) between January 1995 and December 2004. Database information for patients with a diagnosis of 'pulmonary hemorrhage' was further supplemented by review of medical records to identify patients with alveolar hemorrhage.
Alveolar hemorrhage was diagnosed using strict clinical criteria, which included acute onset of hypoxemia with presence of diffuse pulmonary infiltrates on a chest X-ray or computed tomography scan and progressively bloodier return on bronchoalveolar lavage (BAL). Alveolar hemorrhage was further classified as diffuse alveolar hemorrhage (DAH) if no infection was identified within 1 week of diagnosis, or infection associated alveolar hemorrhage (IAH) if microorganisms (excluding Aspergillus spp) were isolated from blood, BAL, or tracheal aspirate within 1 week of onset of alveolar hemorrhage. Patients were excluded from this analysis if: (1) alveolar hemorrhage was diagnosed by clinical or radiological findings only without concurrent BAL, (2) alveolar hemorrhage was diagnosed on autopsy only without antemortem BAL, or (3) BAL findings did not meet our study definition of alveolar hemorrhage.
Study methods
BAL fluid was visually examined to determine the presence of alveolar hemorrhage and was submitted for cytologic evaluation using potassium hydroxide, Giemsa and Papanicolau stains, and appropriate microbiologic examinations for bacteria, fungi, mycobacteria, Pneumocystis carinii, and viruses. Tracheal aspirates, in addition to BAL, were obtained in some intubated patients within 1 week of diagnosis of alveolar hemorrhage and were sent for similar cytologic and microbiologic examination. Blood was also routinely sent for bacterial and fungal cultures.
Treatment of alveolar hemorrhage Alveolar hemorrhage was treated with supportive measures including correction of platelet and coagulation abnormalities, maintenance of fluid and electrolyte balance, aggressive ventilatory and oxygen support, and use of prophylactic and empiric antibiotics as clinically indicated. IAH patients also received appropriate antibiotics for treating their underlying infection. Corticosteroids, if administered, consisted of a standard regimen of high-dose methylprednisolone given in doses of 500 mg twice a day for 3 days, followed by 250 mg twice a day for 3 days, 125 mg twice a day for 3 days, 60 mg twice a day for 3 days, and then 60 mg once a day tapered off over a period of 2 months.
Treatment regimen
Indications for using a RIC instead of MAC regimen included (1) age 455 years with matched related donor or age 445 years with matched unrelated donor, (2) extensive prior therapy including prior HCT, and/or (3) poor performance status including major comorbidity.
RIC regimen consisted of either Cy/Flu/TBI (n ¼ 15, cyclophosphamide (Cy) 50 mg/kg intravenously (i.v.) (day -6), fludarabine (Flu) 40 mg/m 2 i.v. daily (days -6 through -2), and 200 cGy total body irradiation (TBI) (day -1)) or Bu/ Flu/TBI (n ¼ 3) where busulfan (Bu) 2 mg/kg orally every 12 h (days -8, -7) was substituted for Cy. Patients undergoing HCT using MAC received either Cy/TBI (n ¼ 74, Cy 60 mg/kg i.v. (days -6, -5) and TBI 165 cGy twice daily (days -4 through -1)) or Bu/Cy (n ¼ 11, Bu 1 mg/kg orally every 6 h (days -9 through -6) and Cy 50 mg/kg i.v. (days -5 through -2)).
Study definitions and statistical analysis
Time of neutrophil engraftment was defined as the first of three consecutive days with an absolute neutrophil count of X0.5 Â 10 9 /l. The period within 5 days of neutrophil engraftment was defined as peri-engraftment period. Onset of hemorrhage within 30 days of HCT was classified as early alveolar hemorrhage, whereas that occurring after 30 days was called late alveolar hemorrhage.
The cumulative incidence of alveolar hemorrhage was calculated by treating deaths from other causes as competing risks. 7 Comparison of patient characteristics was done using the w 2 test, Fisher's exact test, or Wilcoxon's rank sum test, as appropriate. 8 Probability of overall survival at 60 days from the onset of DAH was calculated using the Kaplan-Meier method with 95% confidence intervals (CI) derived from the standard errors. 9 Survival curves were compared using the log-rank test. Multivariate Cox regression analysis was performed for overall survival to adjust for age at transplantation and donor source. All P-values reported are two-sided and a P-value of less than 0.05 was considered statistically significant. Data analysis was performed using the SAS software, version 8.0 (Cary, NC, USA). The analysis was performed in December 2005.
Results
Alveolar hemorrhage as a pulmonary complication was identified in 103 allogeneic HCT recipients (RIC ¼ 18, MAC ¼ 85). The cumulative incidence of alveolar hemorrhage at 180 days following RIC HCT was 8% (95% CI, 5-11%) compared to 7% (95% CI, 6-8%) in those receiving HCT using MAC (P ¼ 0.56) (Figure 1 ).
Patient and transplant characteristics of the 18 patients developing alveolar hemorrhage following HCT using RIC are outlined in Table 1 . The indications for transplant were acute myeloid leukemia (n ¼ 5), myelodysplastic syndrome (n ¼ 4), chronic myeloid leukemia (n ¼ 3), non-Hodgkin's lymphoma (n ¼ 3), Hodgkin's lymphoma (n ¼ 2), and X-linked lymphoproliferative disease (n ¼ 1). RIC was used instead of MAC because of older age (445 years for UCB or 455 years for MRD, n ¼ 12), coexisting comorbidities (n ¼ 6), or history of extensive prior therapy (n ¼ 6); five patients had two or more of these high-risk features. Coexisting comorbidities included chronic hepatitis C (n ¼ 1), left ventricular ejection fraction o50% (n ¼ 4), and abnormal pulmonary function tests (FEV1 or DLCO o50% predicted, n ¼ 1). Six patients had received a prior autologous (n ¼ 5) or allogeneic (n ¼ 1) HCT. Hemorrhage occurred within 60 days of transplant in 16 patients. Sixteen patients had severe hemorrhage requiring intubation and ventilatory support.
Twelve patients had IAH. These included nine patients with microorganisms isolated from BAL or tracheal aspirates only (coagulase-negative Staphylococcus spp (n ¼ 3), Candida albicans (n ¼ 1), cytomegalovirus (n ¼ 1), Enterobacter cloacae (n ¼ 1), Enterococcus spp (n ¼ 1), Pseudomonas aeruginosa (n ¼ 1), and respiratory syncytial virus (n ¼ 1)), two patients with positive blood cultures only (both with coagulase-negative Staphylococcus spp), and one patient with S. aureus isolated from both BAL and blood. Within the IAH and DAH subgroups, time to hemorrhage onset from HCT, time to neutrophil engraftment, time between hemorrhage and neutrophil engraftment and absolute neutrophil count (ANC) at the onset of hemorrhage were comparable using either RIC or MAC regimens. Survival at 60 days from the onset of hemorrhage was 28% (95% CI, 7-49%) for patients developing alveolar hemorrhage after RIC and was comparable to that observed with hemorrhage following MAC HCT (60-day survival 26% (95% CI, 17-35%), P ¼ 0.56) (Figure 2 ). Survival did not differ between the two groups after adjusting for age at transplantation and stem cell source (hazard ratio 1.3 (95% CI, 0.6-2.7), P ¼ 0.52). Of the five patients from the RIC HCT cohort who survived for more than 60 days from hemorrhage onset, one is still alive with normal pulmonary function at 14 months, whereas three patients died from progression of their underlying disease and one patient died from recurrent alveolar hemorrhage.
Age at transplant, presence of infection, donor source, time between hemorrhage and engraftment, ANC at the time of hemorrhage, presence of acute graft-versus-host disease (GVHD), or use of corticosteroids did not predict 60-day survival on univariate analysis. 
Discussion
The incidence, clinical presentation and outcome of alveolar hemorrhage occurring after RIC allogeneic HCT is similar to that seen after transplantation using MAC and is associated with very high mortality. Although the precise mechanism of post transplant alveolar hemorrhage is not known, it is postulated to be multifactorial in origin with endothelial and alveolar damage due to chemotherapy, radiation therapy, graft-versus-host-disease (GVHD), circulating inflammatory mediators, underlying infections, and altered cardio-pulmonary hemodynamics contributing to its pathogenesis. 2, 4 Decreasing the intensity of the preparative regimen using RIC may not be protective against the development of this syndrome as the other etiologic factors remain. Also, older age and a higher prevalence of comorbidities might account for the higher than expected incidence of this syndrome in patients undergoing RIC HCT.
Most studies of post-HCT alveolar hemorrhage have focused exclusively on DAH and have excluded patients with IAH. However, pulmonary infections are frequent in the post transplant period, are often underdiagnosed, and can contribute to the pathogenesis of alveolar hemorrhage. 10, 11 Furthermore, it is difficult to distinguish microbial colonization from infection in the immunocompromised HCT recipient and we have previously reported that post transplant IAH and DAH are similar high-risk syndromes. 2 We have defined IAH and DAH using very strict clinical criteria and have analyzed patients with both syndromes in this study.
Early onset hemorrhage and hemorrhage occurring in the peri-engraftment period have been reported to be favorable prognostic factors for post transplant alveolar hemorrhage, possibly due to the transient nature of lung injury caused by the release of inflammatory cytokines by recovering neutrophils.
1,2 These factors were not associated with better survival in patients undergoing RIC HCT with alveolar hemorrhage. This could be related to the lesser extent of myelosuppression occurring with RIC when compared to MAC regimens; however, the relatively small sample size of our cohort limits our opportunities and statistical power for such correlations.
Despite the lack of well-controlled trials, high-dose corticosteroids have been widely used for the treatment of this syndrome, albeit with disappointing results. [1] [2] [3] [4] 12 Notwithstanding the limitation of small sample size, we observed no benefit with high-dose corticosteroids in hemorrhage occurring after RIC allogeneic HCT. Although all patients with DAH and the majority of patients with IAH in our RIC cohort received high-dose methylprednisolone, 60-day survival from hemorrhage onset was only 28%. Recombinant factor VII has been reported to help in the management of post transplant alveolar hemorrhage, 13 however larger experience with this agent is needed before it can be recommended for routine clinical use.
